EUVIMEDEUVIMED entdecken
Crossref

The Efficiency of Adalimumab in Cases of Chronic Methotrexate-Resistant Juvenile Idiopathic Arthritis-Associated Anterior Uveitis: Retrospective Case Series Study

E. V. Gaidar, M. M. Kostik, M. F. Dubko, V. V. Masalova, L. S. Snegireva, E. A. Isupova, T. N. Nikitina, E. D. Serogodskaya, O. V. Kalashnikova, V. G. Chasnyk

Pediatric pharmacology · 2016

DOI: 10.15690/pf.v13i4.1605 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric pharmacology, 2016. Verfasst von E. V. Gaidar und 9 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Juvenile idiopathic arthritis (JIA) associated uveitis may be the cause of not only visual acuity decrement, but also blindness. At the same time, in some patients therapy with methotrexate can not prevent the development of these complications.

Objective

Our aim was to investigate the efficiency and safety of using a tumor necrosis factor inhibitor (adalimumab) in patients with JIA-associated uveitis.

Methods

We conducted a retrospective single-arm study of a series of cases. The results of using adalimumab were evaluated in patients with JIA-associated chronic anterior uveitis, who have been under observation for no less than 1 year before and after starting using adalimumab. The latter was prescribed due to progressing and/or recidivous methotrexate-resistant uveitis.

Results

We have analyzed clinical case records of 36 children with JIA-associated uveitis. At the start of therapy with adalimumab, actual uveitis was diagnosed in 30 (83%) patients. Remission was achieved in 29 of 30 cases in 2 (2; 12) weeks in patients with actual uveitis. 11 (31%) patients had a uveitis exacerbation 28 (13; 69) weeks after adalimumab therapy started. Adalimumab reduced the exacerbation frequency from 4 (1; 9) to 0 (0; 1) exacerbations per year for one patient (p < 0,001), and reduced the proportion of patients who were treated with topical glucocorticosteroids (from 83 to 8%). There were no differences (in achieving remission and reducing exacerbation frequency) with regard to patients’ sex, involvement of one or both eyes in the disease onset, antinuclear factor seropositiveness, uveitis type and character of joints affection.

Conclusion

Adalimumab promotes fast and long-lasting remission of JIA-associated methotrexate-resistant uveitis.

Zitieren

APA

Gaidar, E. V., Kostik, M. M., Dubko, M. F., Masalova, V. V., Snegireva, L. S., Isupova, E. A., Nikitina, T. N., Serogodskaya, E. D., Kalashnikova, O. V., & Chasnyk, V. G. (2016). The Efficiency of Adalimumab in Cases of Chronic Methotrexate-Resistant Juvenile Idiopathic Arthritis-Associated Anterior Uveitis: Retrospective Case Series Study. Pediatric pharmacology. https://doi.org/10.15690/pf.v13i4.1605

Vancouver

Gaidar EV, Kostik MM, Dubko MF, Masalova VV, Snegireva LS, Isupova EA, et al. The Efficiency of Adalimumab in Cases of Chronic Methotrexate-Resistant Juvenile Idiopathic Arthritis-Associated Anterior Uveitis: Retrospective Case Series Study. Pediatric pharmacology. 2016. doi:10.15690/pf.v13i4.1605

BibTeX
@article{Gaidar2016,
  author = {Gaidar, E. V. and Kostik, M. M. and Dubko, M. F. and Masalova, V. V. and Snegireva, L. S. and Isupova, E. A. and Nikitina, T. N. and Serogodskaya, E. D. and Kalashnikova, O. V. and Chasnyk, V. G.},
  title = {The Efficiency of Adalimumab in Cases of Chronic Methotrexate-Resistant Juvenile Idiopathic Arthritis-Associated Anterior Uveitis: Retrospective Case Series Study},
  journal = {Pediatric pharmacology},
  year = {2016},
  doi = {10.15690/pf.v13i4.1605}
}
Kostenlos starten →